Keyphrases
Anaplastic Large Cell Lymphoma
100%
Patient-reported Outcomes
100%
Hodgkin Lymphoma
100%
Brentuximab Vedotin
100%
Health-related Quality of Life
42%
Relapsed Lymphoma
28%
Response Rate
14%
Relapsed or Refractory
14%
Large Population
14%
Remission Rate
14%
Patient Assessment
14%
Cancer Patients
14%
Physical Activity
14%
Phase II Trial
14%
Stem Cell Transplantation
14%
Daily Activities
14%
Small Sample Size
14%
Survival Time
14%
Treatment Decisions
14%
Life Challenges
14%
Patient-Reported Outcomes Measurement Information System (PROMIS)
14%
Overall Health
14%
Activity Capacity
14%
Patient-reported Health
14%
Long-term Survivors
14%
Assessment Instrument
14%
Poor Prognostic
14%
Validated Assessment
14%
Prognostic Outcome
14%
Energy Levels
14%
Outlook on Life
14%
Questionnaire Assessment
14%
Medicine and Dentistry
Patient-Reported Outcome
100%
Hodgkin's Lymphoma
100%
Anaplastic Large Cell Lymphoma
100%
Brentuximab Vedotin
100%
Quality of Life
42%
Malignant Neoplasm
14%
Spontaneous Remission
14%
Physical Activity
14%
Stem Cell Transplant
14%
Phase II Trials
14%
Survival Time
14%
Pharmacology, Toxicology and Pharmaceutical Science
Hodgkin Disease
100%
Brentuximab Vedotin
100%
Anaplastic Large Cell Lymphoma
100%
Malignant Neoplasm
14%
Remission
14%
Phase II Trials
14%
Survival Time
14%
Biochemistry, Genetics and Molecular Biology
Brentuximab Vedotin
100%
Physical Activity
14%
Sample Size
14%
Stem Cell Transplant
14%
Survival Time
14%
Phase II Trials
14%